JPMorgan Ultra Short Income ETF vs Tilray Brands Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.29 (market cap $42.37B), while Tilray Brands Inc trades at $3.49 (market cap $530.54M). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 79.9× Tilray Brands Inc's market cap, and JPMorgan Ultra Short Income ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 46 Days and Tilray Brands Inc for 31 Days on average.
| JPST | TLRY | |
|---|---|---|
Market Cap | $42.37B | $530.54M |
Volume | 7,889,185 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $21.00 |
52-Week Low | $50.22 | $3.57 |
Typical Hold Time | 46 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
JPMorgan Ultra-Short Income ETF (JPST) trades at $50.27 with minimal daily movement (+0.04%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent institutional activity shows mixed sentiment with some firms reducing positions while others increased holdings. The fund continues its regular $0.17 dividend payments, maintaining income distribution consistency.
JPST faces headwinds from rising interest rate environment while benefiting from demand for ultra-short duration strategies. The ETF's active management approach has shown recent underperformance versus peers, creating both opportunity for yield-seeking investors and risk from competitive pressure. Market volatility continues to drive flows into cash-alternative strategies.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →